Insilico Medicine reports a response rate for ISM6331 in Phase 1 mesothelioma study
The company reported a response rate at the 130 mg dose in a Phase 1 mesothelioma study.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Insilico Medicine Reports 40% Response Rate in Phase 1 Trial
Insilico Medicine reported a 40% response rate at 130 mg for ISM6331 in a Phase 1 mesothelioma trial.